[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nabiqasim Industries (Pvt) Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,82,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100582394","phase-4-glycemic-control-with-triple-pathway-approach-through-empagliflozin-linagliptin-and-metformin-combination-100582394",false,"NCT06862739","Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin","GLYCO-3P","Inclusion criteria\n\n1. Patients of any gender\n2. Patients aged between 18-80 years\n3. Patients having HbA1c 8 % or above\n4. Patients diagnosed with type II diabetes (more than at least 06 months)\n5. Patients already on at least 02 or more anti-diabetic agents\n6. Patients not allergic to empagliflozin, linagliptin, or metformin\n\nExclusion criteria\n\n1. Patients with age less than 18\n2. Patients with Type-I diabetes\n3. Patients having diabetes for less than 06 months\n4. Patients on GLP-1 and GIP\n5. Patients who are pregnant or lactating females\n6. Patients with decompensated chronic liver disease (DCLD)\n7. Patients with eGFR less than 30 ml\n8. Patients with end-stage heart failure (NYHA Class 4)\n9. Patients who are allergic to empagliflozin, linagliptin, or metformin\n10. Patients who are not willing to consent\n11. Patients who are unable to give medical history","ALL","18 Years","80 Years",{"count":21,"type":22},800,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.",[28,29],"Diabetes Mellitus","Type 2 DM",[31,32,33,34,35,36,37,38,39,40,29],"Combination","empagliflozin","metformin","linagliptin","compliance","Hypoglycemic events","weight management","quality of life","treatment satisfaction","glycemic control","RECRUITING","2026-04-14",{"date":44,"type":45},"2026-04-17","ACTUAL",{"date":47,"type":45},"2025-10-30",{"date":49,"type":22},"2026-06-30",{"name":51,"class":52},"Nabiqasim Industries (Pvt) Ltd","INDUSTRY",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100619586","redcure-registry-for-chronic-kidney-disease-ckd-anemia-100619586","NCT07346547","REDCURE Registry for Chronic Kidney Disease (CKD) Anemia","Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)","REDCURE","Inclusion Criteria:\n\n* Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)\n\n  * Patients on hemodialysis (HD) or peritoneal dialysis (PD)\n  * Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD\u002FPD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent\n\nExclusion Criteria\n\n1. Acute Kidney Injury (AKI) without underlying chronicity\n2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)\n3. Refusal or inability to provide consent\n4. Current enrollment in an interventional trial that restricts real-world data collection\n5. Life expectancy \\\u003C 3 months, where follow-up is not feasible\n6. Known contraindications to Daprodustat as per local prescribing information",{"count":63,"type":22},384,"3 Months","OBSERVATIONAL","A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat",[68],"CKD Anemia",[70,71,72],"Daprodustat","oral HIF PHI","CKD anemia","NOT_YET_RECRUITING","2026-01-15",{"date":76,"type":45},"2026-01-20",{"date":78,"type":22},"2026-01-30",{"date":80,"type":22},"2027-05-31",{"name":51,"class":52},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":65,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":106,"locationsCount":4},"100620360","primary-care-erectile-function-outcome-registry-for-men-100620360","NCT07356609","Primary Care ERectile Function Outcome Registry for Men","PERFORM","Inclusion Criteria:\n\n1. Adult male above 18 years of age\n2. Married\n3. Diabetic\n4. Patient reports erectile dysfunction (symptomatic).\n5. Patient is eligible to be prescribed sildenafil by treating clinician.\n\nExclusion Criteria:\n\n1. If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)\n2. Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate\u002Fdinitrate) - absolute contraindication\n3. Recent or unstable cardiovascular disease\n\n   * Myocardial infarction or stroke in last 3 months\n   * Unstable angina\n   * Uncontrolled arrhythmia or heart failure NYHA III-IV\n   * Resting hypotension (SBP \\\u003C 90 mmHg) or uncontrolled hypertension (SBP \\> 180 mmHg) per treating clinician\n   * Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe)\n   * Known hypersensitivity to sildenafil or excipients\n   * Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan\u002Fdose adjustment","MALE",{"count":91,"type":22},255,"12 Months","The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.",[95],"Erectile Dysfunction",[97,98,99],"Erectile dysfunction","male reproductive health","male sexual health","2026-01-14",{"date":102,"type":45},"2026-01-21",{"date":104,"type":22},"2026-02-06",{"date":80,"type":22},{"name":51,"class":52},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100612146","phase-4-resmiterom-efficacy--safety-in-patients-with-mash-100612146","NCT07249788","Resmiterom Efficacy & Safety in Patients With MASH","Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study","REZMASH","Inclusion Criteria:\n\n* • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)\n\n  * Clinical diagnosis of MASH using:\n\n    * LSM ≥ 8.5kpa And\u002For\n    * FAST score ≥0.67 And\u002For\n    * FibroScan CAP ≥ 275 dB\u002Fm And\u002For\n    * FIB-4 \\> 1.3\n\nExclusion Criteria:\n\n* • History of drug addiction and alcoholism\n\n  * Cirrhosis or decompensated liver disease\n  * Chronic viral hepatitis HBV, HCV)\n  * MACE including MI, Stroke, PE etc.\n  * Pregnant\u002Flactating women\n  * Concurrent use of other investigational drugs\n  * History of other liver diseases (viral, autoimmune, drug-induced, alcohol)\n  * Previous use of resmetirom in last 6 months\n  * Significant renal impairment (eGFR \\\u003C30)","75 Years",{"count":117,"type":22},165,[25],"Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.",[121],"MASH - Metabolic Dysfunction-Associated Steatohepatitis",[123,124,125,126],"Resmetirom","MASH","Safety","Efficacy","2025-11-25",{"date":129,"type":45},"2025-12-03",{"date":131,"type":45},"2025-10-17",{"date":133,"type":22},"2026-12-31",{"name":51,"class":52},1,""]